S. A. Makarov

S. A. Makarov

Auto-generated profile, based on publicly available information

S. A. Makarov

Saint Petersburg State University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2022 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
VSV. V. Strizheletsky
V. V. Strizheletsky
YGYulia Gomon
Yulia Gomon
ЕSЕ. А. Spichakova
Е. А. Spichakova
АKА. S. Kolbin
А. S. Kolbin
АKА. А. Kalyapin
А. А. Kalyapin
FSF. М. Sultanova
F. М. Sultanova
Objective: аssessment of orlistat, liraglutide and sibutramine consumption in the Russian Federation as drugs recommended by the Russian clinical guidelines for the pharmacotherapy of obesity.Material and methods. From IQVIA database, the information was selected on retail sales and procurement of the specified drugs at the expense of the federal and regional budgets in the period of 2011–2021. The consumed volumes of each drug were recalculated into the number of defined daily doses (DDDs) for each international nonproprietary name in accordance with the World Health Organization methodology.Results. It was demonstrated that over a 10-year period there was a tendency to reduce the consumption of drugs for the treatment of obesity from 83.03 million DDDs in 2011 to 71.7 million in 2021. Sibutramine consumption dominated throughout the observation period: its share ranged from 76% to 84%. The proportion of people receiving obesity pharmacotherapy in the Russian Federation was about 0.5%. Herewith 58–66% of DDDs sales took place in 3 regions: Moscow, Moscow Region and Saint Petersburg.Conclusion. Low efficacy, high frequency of adverse effects, frequent weight gain after therapy termination, as well as low orientation of doctors to the need for pharmacotherapy are probably the main factors determining the low prevalence of using drugs for the treatment of obesity in Russia.

23 April 2023 in Endoscopic Surgery
Verified
Journal Article
Closed access
VSV.V. Strizheletsky
V.V. Strizheletsky
YGYulia Gomon
Yulia Gomon
ESE.A. Spichakova
E.A. Spichakova
AKA.S. Kolbin
A.S. Kolbin
SMS.A. Makarov
S.A. Makarov
DBD.S. Budanov
D.S. Budanov
Objective. The purpose of this study was to evaluate the economic efficiency of using surgical tactics for the treatment of obesity at the expense of the healthcare system of the Russian Federation. Material and methods. An analysis of the impact on the budget was carried out, within which the costs of the healthcare system for providing care to obese patients were modeled in the event of an increase in the proportion of people who underwent bariatric interventions. The data obtained in the framework of a previously conducted case—control study (A. Aminian et al., 2019) regarding the achievement of clinical outcomes in the group of conservative and surgical management of patients were selected as information on the effectiveness. Direct medical costs are taken into account. Annual 5% cost discounting has been applied. Results. The total cost per 1 patient for 8 years in the surgical treatment group is 1.109.407 rubles, in the conservative treatment group — 1.242.501 rubles. The total difference in costs per 1 patient over 8 years is 133.093 rubles in favor of a group of operated patients, which does not cover the costs associated with surgical intervention in case of reimbursement of costs at the expense of the healthcare system. The increase in costs in all variants of the simulated practice for the entire simulated population of obese patients in the Russian Federation over an 8-year period amounted to no more than 0.068% of the costs of the healthcare system. The minimum increase (0.03% of all costs) was a variant of practice, when about 6.000 surgical interventions are performed annually at the personal expense of patients and another 1.000 at the expense of the budget of the healthcare system. Conclusions. Currently, about 1.5 million people in the Russian Federation need surgical treatment for obesity, while in real practice access to this type of medical care is extremely limited. The results of this study can be used as support in decision-making on the development of a comprehensive national strategy for financing medical care for patients with obesity and related diseases.


2 May 2020 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
VSV. V. Strizheletsky
V. V. Strizheletsky
GRG. M. Rutenburg
G. M. Rutenburg
SMS. A. Makarov
S. A. Makarov
ISI. I. Suvorov
I. I. Suvorov
RRR. B. Ramazanov
R. B. Ramazanov
ALA. N. Luchkin
A. N. Luchkin
Лапароскопические вмешательства при рецидивных паховых грыжах

1 January 2022 in Endoscopic Surgery
Verified
Journal Article
Closed access
SMS.A. Makarov
S.A. Makarov
VAV.P. Armashov
V.P. Armashov
ABA.M. Belousov
A.M. Belousov
AKA.S. Kupriyanova
A.S. Kupriyanova
NMN.L. Matveev
N.L. Matveev
ЦЕЛЬ ИССЛЕДОВАНИЯ Так как LapIPOM в настоящее время оспаривается новыми минимально инвазивными экстраперитонеальными методами пластики вентральных грыж, представляется целесообразным опубликовать подробный анализ результатов LapIPOM, который может помочь точнее определить место этой операции в спектре методов лечения вентральных грыж. МАТЕРИАЛ И МЕТОДЫ Проанализирована проспективная группа из 247 пациентов, 70 (28,3%) мужчин, которым была выполнена LapIPOM по поводу первичной или послеоперационной срединной вентральной грыжи. Выполнены 253 лапароскопические герниопластики IPOM (80 при послеоперационных и 173 при первичных грыжах). Описана стандартизированная техника операции. Прослежены периоперационные и ранние послеоперационные (до 30 сут) результаты, которые сравнивали с таковыми сопоставимых серий, опубликованных за последние два десятилетия. РЕЗУЛЬТАТЫ Средняя длительность операции при первичных грыжах составила 47 мин, при послеоперационных — 82 мин. Частота энтеротомий достигала 2,5% при послеоперационных грыжах и 0 при первичных грыжах, в среднем 0,79%. Глубокой инфекции в области хирургического вмешательства не было, поверхностная составила менее 2%. Средняя оценка послеоперационной боли по аналоговой шкале при выписке была 2,91. Повторных госпитализаций и операций, связанных с хирургическим лечением грыж, за 30-дневный послеоперационный период не было. ЗАКЛЮЧЕНИЕ Краткосрочное наблюдение за пациентами показывает, что LapIPOM в рамках показаний имеет ряд преимуществ перед другими видами герниопластики: она выполняется относительно быстро, легко воспроизводится, сохраняет целостность неизмененных отделов брюшной стенки и сопровождается минимальными осложнениями.

24 May 2024 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
ABA.M. Belousov
A.M. Belousov
SNS.L. Nepomnyashchaya
S.L. Nepomnyashchaya
VDV.N. Danilin
V.N. Danilin
KTK.O. Timofeeva
K.O. Timofeeva
VAV.P. Armashov
V.P. Armashov
NMN.L. Matveev
N.L. Matveev
Objective. The purpose of the study was to evaluate the results of using fluoropolymer-coated mesh during intraperitoneal onlay mesh hernia repair in patients with primary ventral hernias. Material and methods. The multicenter, non-randomized, controlled clinical study included 88 patients of both sexes who were operated on using a laparoscopic approach using the IPOM technique for a primary ventral hernia. The duration of observation ranged from 3 to 12 months. In the main group, 48 patients received fluoropolymer-coated meshes (Ftorex). A comparison was made with a retrospective group of 40 patients who were treated with anti-adhesive collagen-coated meshes (Parietene composite, Parietex Composite, Symbotex). Results. The number of early and late postoperative complications in the groups did not have significant differences, at the same time, their number was lower in the group of patients in whom fluoropolymer-coated meshes were used. Most of the complications corresponded to Clavien—Dindo class I and II and did not pose a significant threat to health. There were no recurrences of hernias observed in patients included in the study. There were slightly more adhesions in the fluoropolymer-coated mesh group (35.4% vs. 25.0% in the collagen-coated mesh group). The quality of life of patients in the study groups did not differ. Conclusion. In laparoscopic IPOM hernia repair fluoropolymer-coated meshes are not inferior in effectiveness and safety to traditionally used collagen-coated meshes and can be recommended for use in patients with primary ventral hernias.